Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab after R-CHOP debulking for Richter transformation
2018-003483-32Phase 2Completed
- Sponsor
- Filo
- Start
- Mar 2019
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab in diffuse large B-cell lymphoma (DLBCL), sponsored by Filo. Primary endpoint: Complete remission rate at week 16. Started Mar 2019; status: completed.
02
Drugs
blinatumomab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2018-003483-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003483-32.